SUM149PT cell line treated with AKTi (ipatasertib) and EZH2i (tazemetostat). SUM149PT cell line treated with AKTi (ipatasertib) and EZH2i (tazemetostat)

SUM149PT cell line treated with AKTi (ipatasertib) and EZH2i (tazemetostat). Overall design: On day -5, SUM149PT cells were seeded at 40% confluency and treated with 5uM tazemetostat or DMSO. On day -3, cells were passaged again at 40% confluency and maintained in DMSO or tazemetostat. On day -1, cells were seeded into 6cm plates at 250,000 cells per plate and maintained in DMSO or tazemetostat. On day 0, cells were treated in media containing 2% FBS with AKTi (ipatasertib) and/or EZH2i (tazemetostat). Cells were collected at 24 hours, RNA was isolated and then sequenced using NGS.